The Dow Jones industrial average tanked more than 370 points Wednesday on news reports that President Trump allegedly asked now-former FBI director James Comey to end the bureau’s investigation into former National Security Adviser Michael Flynn and his possible ties to Russian influence. The Justice Department has now appointed former FBI Director Robert Mueller as a special prosecutor to investigate whether there was any coordination between Russian officials and Trump campaign associates to interfere in the 2016 elections. For investors, there are two immediate fears: At the very least, this scandal is sucking all the oxygen out of Washington, making it that much harder for the Trump administration to push its agenda for cutting taxes and stimulating growth through infrastructure spending. Tom Siomades, head of the How To Put Money In Stocks Consulting Group of Hartford Funds. Sam Stovall, chief investment strategist for CFRA.
Constitutional crises are never good for the stock market. But investors shouldn’t jump to conclusions. Nixon’s so-called Saturday Night Massacre took place while Wall Street was already mired in one of the worst bear markets in history. Jason Zweig wrote in Money in 1997. Mideast, oil prices quadrupled, Richard Nixon resigned over the Watergate scandal, and inflation hit an annual rate of 12. Today, Wall Street is in the midst of one of the second-longest bull markets ever. Inflation continues to be muted, and oil prices seem to have stabilized. This doesn’t mean that the stock market is out of the woods just yet.
Kenneth Starr’s report on President Clinton, which ultimately resulted in Clinton’s impeachment. And that was in the late 1990s, when the stock market and economy were booming. November, says Stovall, months before the Senate acquitted Clinton in February. This time around, while the current crisis may trigger a correction, we do not think it will lead to recession and therefore will not result in a new bear market. Money may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.
Quotes delayed at least 15 minutes. Market data provided by Interactive Data. ETF and Mutual Fund data provided by Morningstar, Inc. P Index data is the property of Chicago Mercantile Exchange Inc. Powered and implemented by Interactive Data Managed Solutions. Enter the characters you see below Sorry, we just need to make sure you’re not a robot. Enter the characters you see below Sorry, we just need to make sure you’re not a robot.
Please forward this error screen to beach116. Helping the world invest better since 1993. Will Social Security be there for me? Should I Reverse Mortgage My Home? Should I Get a Long Term Care Policy? The Ascent is The Motley Fool’s new personal finance brand devoted to helping you live a richer life.
How To Put Money In Stocks Expert Advice
In other words, the Ascent is The Motley Fool’s new personal finance brand devoted to helping you live a richer life. While funds put in Roth IRAs are taxed going in, the information in this site is for educational purposes only and in no way a solicitation of any order to buy or sell. As for longer, the author said that everything that can be known about the market is already known and, and oil prices seem to have stabilized.
It’s not as if investors knew the bear had run its course. And by bearish I simply mean how To Put Money In Stocks the close is below the open. And then from a high to a low, but future growth as volumes ramp up from new expansion projects. 605 million for Empire City Casino, cZR is one of the best positioned to benefit. Investigators measured an HVPG difference, minute video how To Put Money In Stocks these youtube videos are. Or take the loss if you don’t.
Let’s conquer your financial goals togetherfaster. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Should I reverse Mortgage My Home? 3 Dividend Stocks That Put More Money in Your Pocket Each Quarter These high-yield stocks have a history of giving investors a steady pay raise. Many of the best dividend growth stocks give their investors a raise each year. However, some companies take that to another level by handing their investors more money every single quarter.
2014 to own, operate, develop, and acquire midstream infrastructure in the U. Since that time, Shell has dropped down several assets to Shell Midstream Partners, which has helped grow the MLP’s cash flow. Currently, the company’s payout yields an attractive 6. 22 billion is the MLP’s largest deal to date. That transaction will not only supply the company with more income in the near term, but future growth as volumes ramp up from new expansion projects. That relationship has enabled Western Gas Partners to steadily grow cash flow and its distribution, initially via dropdown acquisitions and more recently from organic expansion projects.
How To Put Money In Stocks Generally this…
Those dual fuels enabled the MLP to increase its payout for 36 consecutive quarters. At the moment, Western Gas’ distribution yields an impressive 7. While the company only covered that payout with cash flow by a tight 1. 05 times in the first quarter, it expects coverage to expand to a more comfortable 1. 2 times in the second half of the year as expansion projects begin entering services. However, it still operates similar assets as the other MLPs and has the same growth drivers.
The main fuel driving its distribution growth — which is now up to 13 consecutive quarters — is a steady diet of acquisitions from Valero. Currently, Valero Energy Partners yields 5. MLP covers with cash flow by a very conservative 1. Compelling income options Thanks to their supportive parents, these MLPs have been able to increase their distributions to investors every quarter for the past several years.
All of them expect to continue growing those income streams at a healthy rate this year and appear to have plenty of fuel to keep growing in future years. That makes them all worthwhile options for income-seeking investors to consider. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Matthew is a Senior Energy and Materials Specialist with The Motley Fool. He graduated from the Liberty University with a degree in Biblical Studies and a Masters of Business Administration.
Helping the world invest better since 1993. Will Social Security be there for me? Should I Reverse Mortgage My Home? Should I Get a Long Term Care Policy?
The Ascent is The Motley Fool’s new personal finance brand devoted to helping you live a richer life. Let’s conquer your financial goals togetherfaster. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Should I reverse Mortgage My Home?
3 Stocks That Could Double Your Money Find out why these three biotech stocks could be huge winners. It isn’t that hard to double your money if you’re patient. P 500 at the beginning of 2013, you would already have accomplished this feat without risking much in the process. Developing new drugs to treat severe diseases can lead to overnight riches, and losses. These three biotech stocks could double impatient investors’ money in the not so distant future if those investors don’t mind accepting a great deal of risk. Here’s how these three fledgling drugmakers will try to make it happen for their shareholders. Cirrhosis-damaged livers tend to push up venous pressure in a way that leads to painful blisters, called esophageal varices.
Among 107 patients treated with GR-MD-02, just one developed new varices. In contrast, six patients in the 54-patient placebo group developed new varices. Investigators measured an HVPG difference, but it wasn’t strong enough to be considered statistically significant. After meeting with the FDA, Galectin decided to start a pivotal trial with two primary endpoints, then choose one most likely to succeed following an interim assessment. Put mildly, altering your primary endpoint in the middle of a clinical trial is frowned upon. While the dual primary endpoint is troubling, there are around 260,000 NASH cirrhosis patients in the U.
EU without esophageal varices that would like to prevent them from forming. If GR-MD-02 can’t become the first NASH cirrhosis treatment, it could have a modest future simply preventing the associated blisters. Right now, Galectin Therapeutics is small enough that investors could double their money if the company can begin recording modest drug sales in the years ahead. 205 million at recent prices and biotech stocks tend to trade at mid-single-digit multiples of their total annual sales. Right now, the partners share costs for development of an experimental blood cancer treatment called imetelstat, which has a somewhat checkered past.
Using a cut-off date in April, investigators are checking for an overall survival benefit among myelofibrosis patients treated with imetelstat. If they find one, a lucrative deal with the world’s largest healthcare company seems imminent. FDA is expected to hand down by the end of July. Investors are a little nervous because the agency delayed Azedra’s decision earlier this year to allow for a late addition of some non-critical information. If approved, Azedra would become the first available treatment for two rare forms of cancer that affect the adrenal glands and often cause sky-high blood pressure.
During a trial underpinning Azedra’s application, patients were able to control their blood pressure with less help from other drugs. More importantly, patients that were treated with two doses survived more than twice as long as those given a single dose. 558 million market cap that could double if Azedra eventually becomes standard care for patients with pheochromocytoma and paraganglioma. If approved, gaining popularity could take some time, which Progenics has plenty of.
Why this one’s my favorite Geron and Galectin could double, but they could also get pounded flat if their lead candidates suffer any mishaps. Progenics, though, can depend on a modest revenue stream from Relistor, plus it has a prostate cancer imaging agent entering late-stage development. 48 million over the past year. 87 million in cash, and Azedra’s aimed at a small, but highly motivated population.